Phio Pharmaceuticals Launches Substantial $6.36M At-The-Market Offering, Potentially Diluting Shares by Over 40%

summarizeSummary

Phio Pharmaceuticals has launched a substantial $6.36 million At-The-Market offering, which could significantly dilute existing shareholders but provides essential capital for advancing its lead clinical program and general operations.

check_boxKey Events

• Launches At-The-Market (ATM) Offering

  Phio Pharmaceuticals Corp. has entered into an At-The-Market offering agreement to sell up to $6.36 million of its common stock through H.C. Wainwright & Co., LLC.

• Significant Potential Dilution

  The offering could result in the issuance of approximately 4.97 million new shares, representing a potential dilution of over 40% to the current 11.62 million outstanding shares, based on a reference price of $1.28 per share.

• Proceeds to Fund Clinical Development and Working Capital

  Net proceeds from the offering are intended to fund the development of PH-762 in an expected Phase 2b/3 clinical trial for cutaneous squamous cell carcinoma, other development activities, and general working capital needs.

• Maximized Under S-3 Public Float Rule

  The $6.36 million offering amount is the maximum permitted under General Instruction I.B.6 of Form S-3, which limits sales to one-third of the company's public float when it is below $75 million.

auto_awesomeAnalysis

Phio Pharmaceuticals Corp. has launched a significant At-The-Market (ATM) offering to sell up to $6.36 million of common stock. This offering, detailed in the prospectus supplement, represents a substantial capital raise for the company, potentially increasing outstanding shares by over 40% based on the last reported sale price of $1.28 per share on April 2, 2026. The proceeds are earmarked for critical funding, including the development of its lead drug candidate PH-762 in an expected Phase 2b/3 clinical trial and general working capital. While highly dilutive for existing shareholders, this capital infusion is crucial for a clinical-stage biopharmaceutical company, especially following previous capital raises that resolved going concern doubts, as noted in the recent 10-K.